Published in Am J Public Health on July 01, 1985
Immunisation: causes of failure and strategies and tactics for success. BMJ (1989) 4.63
Measles control in developing and developed countries: the case for a two-dose policy. Bull World Health Organ (1993) 1.98
Health benefits, risks, and cost-effectiveness of influenza vaccination of children. Emerg Infect Dis (2006) 1.57
Should measles be eradicated? BMJ (1998) 1.50
Return on investment of public health interventions: a systematic review. J Epidemiol Community Health (2017) 1.43
Using a computerized patient record to reengineer an outpatient clinic. Proc Annu Symp Comput Appl Med Care (1994) 1.36
Assessing prevention effectiveness using data to drive program decisions. Public Health Rep (1994) 1.03
Health burden and economic impact of measles-related hospitalizations in Italy in 2002-2003. BMC Public Health (2007) 1.01
Population-based versus practice-based recall for childhood immunizations: a randomized controlled comparative effectiveness trial. Am J Public Health (2012) 1.01
A model for estimating the impact of changes in children's vaccines. Am J Public Health (1995) 0.95
Knowledge synthesis of benefits and adverse effects of measles vaccination: the Lasbela balance sheet. BMC Int Health Hum Rights (2009) 0.95
The average cost of measles cases and adverse events following vaccination in industrialised countries. BMC Public Health (2002) 0.93
Health economics of rubella: a systematic review to assess the value of rubella vaccination. BMC Public Health (2013) 0.91
The president's child immunization initiative--a summary of the problem and the response. Public Health Rep (1993) 0.91
Preventive health care for Medicaid children. Health Care Financ Rev (1990) 0.84
The control of mumps in Israel. Eur J Epidemiol (1999) 0.83
Economic benefits of a routine second dose of combined measles, mumps and rubella vaccine in Canada. Can J Infect Dis (1997) 0.78
Costs and benefits of a second measles inoculation of children in Israel, the West Bank, and Gaza. J Epidemiol Community Health (1990) 0.78
Retracted Predicting the herd immunity threshold during an outbreak: a recursive approach. PLoS One (2009) 0.78
Evaluating the benefits of increasing measles immunization rates. Health Serv Res (2001) 0.77
Mumps in the US Army 1980-86: should recruits be immunized? Am J Public Health (1989) 0.75
Costs of not eradicating measles. Am J Public Health (1985) 0.75
The economic value of life: linking theory to practice. Am J Public Health (1982) 3.03
Medical importance of measles. Am J Dis Child (1962) 2.59
Epidemiologic studies of measles, measles vaccine, and subacute sclerosing panencephalitis. Pediatrics (1977) 2.45
The benefits from 10 years of measles immunization in the United States. Public Health Rep (1975) 1.98
Benefits due to immunization against measles. Public Health Rep (1969) 1.80
Benefit-cost analysis of rubella vaccination policy. N Engl J Med (1976) 1.79
Combined live measles, mumps, and rubella virus vaccines. JAMA (1969) 1.74
Combined live measles, mumps, rubella vaccine. Immunological response. Am J Dis Child (1971) 1.62
Rubella vaccination in the United States: a ten-year review. Epidemiol Rev (1980) 1.53
Cost-benefits of measles eradication: effects of a federal intervention. Policy Anal (1978) 1.19
Persistence of antibody in human subjects for 7 to 10 years following administration of combined live attenuated measles, mumps, and rubella virus vaccines. Proc Soc Exp Biol Med (1980) 1.11
A benefit-cost analysis of mumps vaccine. Am J Dis Child (1982) 1.08
Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27/3) virus vaccines, singly and in combination. Pediatrics (1981) 1.01
Benefits, risks and costs of viral vaccines. Prog Med Virol (1982) 1.00
Clinical evaluation of a new measles-mumps-rubella trivalent vaccine. Am J Dis Child (1975) 0.96
Hospitalizations for measles, 1970-78. Am J Public Health (1982) 0.94
Combined administration of measles, mumps, rubella, and trivalent oral poliovirus vaccines. Public Health Rep (1977) 0.92
The continuing epidemics of obesity and diabetes in the United States. JAMA (2001) 14.84
The spread of the obesity epidemic in the United States, 1991-1998. JAMA (1999) 11.52
Health literacy among Medicare enrollees in a managed care organization. JAMA (1999) 8.63
Nurse case management to improve glycemic control in diabetic patients in a health maintenance organization. A randomized, controlled trial. Ann Intern Med (1998) 7.26
Health reform and the health of the public. Forging community health partnerships. JAMA (1994) 6.18
The relationship between method of physician payment and patient trust. JAMA (1998) 5.56
Field evaluation of vaccine efficacy. Bull World Health Organ (1985) 4.95
Measles antibody: reevaluation of protective titers. J Infect Dis (1990) 3.77
Rational strategy for rubella vaccination. Lancet (1983) 3.61
Patients' trust in their physicians: effects of choice, continuity, and payment method. J Gen Intern Med (1998) 3.51
A descriptive epidemiology of leisure-time physical activity. Public Health Rep (1985) 3.25
Internists' practices in health promotion and disease prevention. A survey. Ann Intern Med (1991) 3.00
Measles vaccine efficacy in children previously vaccinated at 12 months of age. Pediatrics (1978) 2.98
Caloric imbalance and public health policy. JAMA (1999) 2.92
Epidemic diarrhea at Crater Lake from enterotoxigenic Escherichia coli. A large waterborne outbreak. Ann Intern Med (1977) 2.80
The continuing epidemic of obesity in the United States. JAMA (2000) 2.80
Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis (1992) 2.55
A cost-effectiveness analysis of exercise as a health promotion activity. Am J Public Health (1988) 2.46
Barriers to using cost-effectiveness analysis in managed care decision making. Am J Manag Care (2000) 2.41
Patterns of transmission in measles outbreaks in the United States, 1985-1986. N Engl J Med (1989) 2.41
Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. JAMA (1987) 2.28
Preventive therapy with isoniazid. Cost-effectiveness of different durations of therapy. JAMA (1986) 2.18
A persistent outbreak of measles despite appropriate prevention and control measures. Am J Epidemiol (1987) 2.13
Congenital rubella syndrome in the United States, 1970-1985. On the verge of elimination. Am J Epidemiol (1989) 2.12
Continuing measles transmission in students despite school-based outbreak control program. Am J Epidemiol (1985) 2.09
Detection by radioimmunoassay of antibodies in human smallpox patients and vaccinees. J Clin Microbiol (1975) 2.01
Risk factors for outbreaks of influenza in nursing homes. A case-control study. Am J Epidemiol (1986) 1.93
From the Center for Disease control: current status of measles in the United States, 1973--1977. J Infect Dis (1978) 1.91
Progress in measles elimination. JAMA (1982) 1.87
A cost-benefit/cost-effectiveness analysis of smoking cessation for pregnant women. Am J Prev Med (1991) 1.84
Prevention and control of type A influenza infections in nursing homes. Benefits and costs of four approaches using vaccination and amantadine. Ann Intern Med (1987) 1.80
Appropriate age for measles vaccination in the United States. Dev Biol Stand (1986) 1.80
An epidemiologic study of the benefits and risks of running. JAMA (1982) 1.76
Pertussis vaccine--an analysis of benefits, risks and costs. N Engl J Med (1979) 1.75
Choice of preventive treatment for isoniazid-resistant tuberculous infection. Use of decision analysis and the Delphi technique. JAMA (1980) 1.74
Cigarette smoking in China. Prevalence, characteristics, and attitudes in Minhang District. JAMA (1995) 1.72
The resurgence of measles in the United States, 1989-1990. Annu Rev Med (1992) 1.72
The case for global eradication of poliomyelitis. Bull World Health Organ (1987) 1.72
Health impact of measles vaccination in the United States. Pediatrics (1985) 1.71
Current status of mumps and mumps vaccine in the United States. Pediatrics (1978) 1.71
Measles outbreak in a vaccinated school population: epidemiology, chains of transmission and the role of vaccine failures. Am J Public Health (1987) 1.70
Duration of live measles vaccine-induced immunity. Pediatr Infect Dis J (1990) 1.70
Outbreak of paralytic poliomyelitis, Taiwan. Lancet (1984) 1.68
Poliomyelitis outbreak in Israel in 1988: a report with two commentaries. Lancet (1990) 1.67
Length-of-stay after delivery: managed care versus fee-for-service. Health Aff (Millwood) (1996) 1.67
Preventing neonatal herpes. The value of weekly viral cultures in pregnant women with recurrent genital herpes. JAMA (1984) 1.59
Pertussis and pertussis vaccine. Reanalysis of benefits, risks, and costs. JAMA (1984) 1.59
Measles outbreak among unvaccinated preschool-aged children: opportunities missed by health care providers to administer measles vaccine. Pediatrics (1989) 1.57
Smallpox vaccination reactions, prophylaxis, and therapy of complications. Pediatrics (1975) 1.55
An explosive point-source measles outbreak in a highly vaccinated population. Modes of transmission and risk factors for disease. Am J Epidemiol (1989) 1.53
Elimination of indigenous measles from the United States. Rev Infect Dis (1983) 1.50
Fetal risk associated with rubella vaccine: an update. Rev Infect Dis (1985) 1.50
The risks of exercise: a public health view of injuries and hazards. Public Health Rep (1985) 1.50
Lipid screening in a managed care population. Public Health Rep (1998) 1.49
Causes of low preschool immunization coverage in the United States. Annu Rev Public Health (1992) 1.45
Closing the gap. Report of the Carter Center Health Policy Consultation. JAMA (1985) 1.44
The effect of disease prior to an outbreak on estimates of vaccine efficacy following the outbreak. Am J Epidemiol (1995) 1.43
A million dollar measles outbreak: epidemiology, risk factors, and a selective revaccination strategy. Public Health Rep (1992) 1.41
Nutrient intake and supplementation in the United States (NHANES II). Am J Public Health (1986) 1.41
Varicella: clinical manifestations, epidemiology and health impact in children. Pediatr Infect Dis (1985) 1.39
DTP vaccine litigation, 1988. Am J Dis Child (1990) 1.39
Measles surveillance--United States, 1991. MMWR CDC Surveill Summ (1992) 1.38
Pertussis--a disease and a vaccine that are not going away. West J Med (1989) 1.35
Major impediments to measles elimination. The modern epidemiology of an ancient disease. Am J Dis Child (1985) 1.32
Increased lead absorption with anemia and slowed nerve conduction in children near a lead smelter. J Pediatr (1976) 1.32
Measles vaccine efficacy: influence of age at vaccination vs. duration of time since vaccination. Pediatrics (1978) 1.30
Chronic disease in the 1990s. Annu Rev Public Health (1990) 1.27
Duroquinol as an electron donor for chloroplast electron transfer reactions. Biochim Biophys Acta (1978) 1.27
Value of stool cultures. Lancet (1980) 1.26
Pertussis and pertussis vaccine: further analysis of benefits, risks and costs. Dev Biol Stand (1985) 1.26
Assessment of susceptibility to measles and rubella. JAMA (1982) 1.26
Universal immunization to interrupt rubella. Rev Infect Dis (1985) 1.25
A benefit-cost analysis of a childhood varicella vaccination programme. Postgrad Med J (1985) 1.24
Imported measles in the United States. JAMA (1982) 1.23
Physician incentives and disclosure of payment methods to patients. J Gen Intern Med (2001) 1.23
Measles and rubella: our remaining responsibilities. Am J Public Health (1983) 1.23
Pertussis epidemic in Oklahoma. Difficulties in preventing transmission. Am J Dis Child (1986) 1.23
The case for global measles eradication. Lancet (1982) 1.23
Measles vaccines. Pediatr Clin North Am (1990) 1.21
Sleeping pills, insomnia and medical practice. N Engl J Med (1979) 1.20
The opportunity and obligation to eliminate rubella from the United States. JAMA (1984) 1.20
Methodologic issues in the evaluation of vaccine effectiveness: measles vaccine at 12 vs. 15 months. Am J Epidemiol (1982) 1.20
Clinical efficacy of rubella vaccine. Pediatr Infect Dis (1983) 1.18
Vitamin and mineral supplement use and mortality in a US cohort. Am J Public Health (1993) 1.18
Neurotoxicity of domoic Acid in cerebellar granule neurons in a genetic model of glutathione deficiency. Mol Pharmacol (2006) 1.18
Current status of mumps in the United States. J Infect Dis (1975) 1.17
Prevalence of hepatitis B surface antigen and antibody at a state prison in Kansas. J Infect Dis (1978) 1.16
Induction of glutamate-cysteine ligase (gamma-glutamylcysteine synthetase) in the brains of adult female mice subchronically exposed to methylmercury. Toxicol Lett (1999) 1.15
A school-based measles outbreak: the effect of a selective revaccination policy and risk factors for vaccine failure. Am J Epidemiol (1990) 1.14
The epidemiologic field investigation: science and judgment in public health practice. Am J Epidemiol (1990) 1.14
Crossing the divide from vaccine technology to vaccine delivery. The critical role of providers. JAMA (1994) 1.13
Methods of assessing the impact of congenital rubella infection. Rev Infect Dis (1985) 1.10
Impact of influenza A in a nursing home. JAMA (1982) 1.10
A benefit-cost analysis of mumps vaccine. Am J Dis Child (1982) 1.08
The plaque-neutralization test as a measure of prior exposure to measles virus. J Infect Dis (1987) 1.07
Live or inactivated poliomyelitis vaccine: an analysis of benefits and risks. Am J Public Health (1988) 1.06
Immunization of asymptomatic HIV-infected children with measles vaccine: assessment of risks and benefits. Med Decis Making (1989) 1.06